1. In Vivo

Bard EP Deal Latest In Boston Scientific’s M&A Revival, Bolsters CRM Business

Boston Scientific’s recent acquisition of Bard Electrophysiology marks the tenth notable acquisition that it has made since 2010. Four of those deals come in cardiac rhythm management, including EP, which is among the fastest-growing device sectors and one that company executives see as a major contributor to future growth.

After sitting on the dealmaking sidelines just a few years ago while trying to figure out how to digest its $27 billion acquisition of Guidant Corp. in 2005, Boston Scientific Corp. is back in the M&A game, which is welcome news to device start-ups worldwide. [See Deal] Its recent acquisition of Bard Electrophysiology (EP), a division of CR Bard Inc., marks the tenth notable acquisition that Boston Scientific has made since 2010. Four of those deals come in cardiac rhythm management (CRM), including EP, which is among the fastest-growing device sectors and one that company executives see as a major contributor to future growth. [See Deal]

Throughout the early 2000s, Boston Scientific was one of the most aggressive strategic acquirers, pioneering the practice of taking small...

More from Deal-Making

More from In Vivo

Rising Leaders 2025: Doxie Jordan, From UNC Graduate To Global Market Strategist

 
• By Jo Shorthouse

Bristol Myers Squibb executive Doxie Jordan discusses his path to global commercial leadership and the principles guiding pharmaceutical market strategy

Podcast: Brain+ CEO Discusses “Groundbreaking” Potential Of CST Assistant For Dementia Patients

 
• By Anabel Costa-Ferreira

Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.

Behind The Buyout: Dispatches From The Dealmaking Table

 
• By Jo Shorthouse

In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.